


Handling the Inspection and Closeout Meeting




Agenda

- annual activities
- pre-inspection activities
- handling activities
- closeout activities



© 2017 Cerulean Associates LLC www.Ceruleanllc.com 2




- Site inspection response team
- Site inspection proof binder
- Sample inspection handling SOP walkthrough
- More policies and SOPs to consider
- Regulatory training (a practical approach)
- If you're going more virtual....

ANNUAL ACTIVITIES

© 2017 Cerulean Associates LLC www.Ceruleanllc.com 3

Five Elements to Keep Current



© 2017 Cerulean Associates LLC www.CeruleanILC.com 4

Site Inspection Response Team

Role	Name	Office Phone	Cell Phone	Email
Quality Assurance				
Back-up				
Regulatory Affairs				
Back-up				
IT				
Back-up				
RIM				
Back-up				
Senior Mng Rep				
Back-up				

© 2017 Cerulean Associates LLC www.CeruleanILC.com 5

Site Inspection Proof Binder

Two sections

- Basic site info and records (e.g., proof)
- Specific/supplemental records

Update Section One annually after QSMR or APR

Reuse internally for:

- your inspection prep
- training personnel on inspection handling
- conducting internal quality audits
- review as a template with critical suppliers



© 2017 Cerulean Associates LLC www.CeruleanILC.com 6

Site Inspection Proof Binder



WHO Guidelines for Drafting a Site Master File (SMF)
www.who.int/publications/en/



PIC/S Explanatory Notes for Pharmaceutical Manufacturers on the Preparation of a Site Master File
www.picscheme.org/publication.php

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

7

Checklist: Binder Contents

In reference materials



© 2017 Cerulean Associates LLC

www.CeruleanILC.com

8

Section 1: Basic Site Info

- Site address, phone #'s, business hours
- Top-level organization chart for site
- Overall site diagram with workflows
 - If sterile lock-down areas are important, make sure to clarify location on diagram and air handling
- List of products made/assembled at site (include reference to any specific NDA/BLA/510K)
- List of products distributed from/stored at site
- List of critical vendors and tier 1 distributors
- Overall quality policy
- Index of SOPs and policies
- List of recent (within past 5 years) inspections and 3rd party audits (and results)
- List of current company certifications and/or awards
- For any nearby sites, add a map showing sites



© 2017 Cerulean Associates LLC

www.CeruleanILC.com

9

Case Study: Section 1 Excerpt

List of Inspections and 3 rd Party Audits over past 5 years			
Type/Scope of Inspection	Inspection Body	Date Performed	Results/Findings
Routine cGCP	ANM – Romania	July 2006	No findings
Routine cGCP	MHRA – UK	January 2007	1 minor finding
Study specific	FDA – US	July-August 2008	4 FDA Form-483 findings, no WL
Routine cGMP	MHRA – UK	October 2010	No findings
GMP for controlled substances	IGZ – Netherlands	May 2011	No findings
ISO 9001 renewal	Cerulean	October 2011	ISO certificate re-issued

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

10

Section 2: Specific Information

Section Two: Specific/Supplemental Info

- Specific SOPs
- Relevant CAPAs or OOS's
- Clinical trial protocols
- Site data integrity compliance plan
- etc.

Very specific to inspection cause

If routine inspection, consider compiling remaining records from Frequently Requested Records list



© 2017 Cerulean Associates LLC

www.CeruleanILC.com

11

Case Study: Section Two

Specifics from a Recall Closeout Inspection:

- List of all consignees (as close to patient as possible, so minimum 1" tier – preferably through 3rd tier)
- Summary Memo to File of the various steps taken with clear timeline of events, from initial realization/complaint to today
- CAPA(s) and investigations associated with (including recreation of event)
- Associated product and QC SOPs (before and after fixes/changes to resolve)
- Any copies of investigations conducted by suppliers who caused/were relevant to recall
- Copies of all press releases, including web and social media announcements (FDA will google beforehand, so you better have copies of all of them ... including from contract sales force)
- Correspondence from any customers certifying they destroyed/dropped of product if they didn't return it
- Spreadsheet of consignee contacts – calls, emails, letter attempts, dates, etc.
- Copies of typical letter/email to consignees
- DMR – before and after (if changed)
- Photos or video of actual destruction process (FDA will take photos when they observe as evidence)



© 2017 Cerulean Associates LLC

www.CeruleanILC.com

12




Where's the Love?

© 2017 Cerulean Associates LLC www.CeruleanILC.com 13

Inspection Handling SOP

- greeting investigators
- establishing proper logistics
- tracking inspection progress
- using an observation-closure matrix
- note-taking and duplicate photo taking
- coordinating employees and contractors interviewed
- answering questions – best practices
- logging documents shown to v. requested by the investigator
- providing samples
- handling affidavits
- correcting observations during an inspection
- managing the closeout meeting




© 2017 Cerulean Associates LLC www.CeruleanILC.com 14

Sample SOP: Inspection Handling

In reference materials

Practical Tip
Try to keep any
“welcome to our firm”
presentation to 15 slides
or less



© 2017 Cerulean Associates LLC www.CeruleanILC.com 15

More Policies/SOPs to Consider

- Policy: Site Visitor Access**
- sign-in logs, visitor badges, web v. LAN access
 - escort of guests
 - providing access to general v. secured areas, documents, systems
 - allowances for photography or videotaping
 - requirement for 15-minute safety orientation for guest workers
- SOP: Responding to Regulatory Agency Inspectional Findings**
- correspondence drafting and reviews
 - provision of proof
- SOP: Tracking Regulatory Agency Communications & Commitments**
- log or tracking spreadsheet as record
 - reviewing progress and communications with management

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

16

Regulatory Training

FDA likes to see everyone be aware of the regulations a firm, its products and processes are under

Timing	Activity
Year 1 (including new hires AND new contractors)	In person training that relates regulations to day-to-day job tasks (SOPS/policies) and a safe/efficacious product
Year 2	Read n’ review or CBT training
Year 3	Lunch and learn session on new or recent, relevant guidance OR Warning Letter to competitor Read n’ review or CBT training
Year 4	In person training (as per Year 1)
For new or revised regulation	In person training (cycle starts anew)

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

17

Considerations If Your Firm is Going More Virtual....

- Where will FDA be situated?
- How will you provide FDA records requested?
- Who will take notes and log records?
- Who will lead the closeout meeting (and push back as necessary/make oral commitments)? Only make commitments you (not your suppliers) have physical control over....
- Who will be responsible for spearheading any response?
- How will you show FDA which supplier is responsible for what regulated activity and records?
- Do your quality agreements clearly document:
 - your accountability
 - suppliers’ responsibilities

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

18

Prepare a Supplier for FDA

Focus on critical suppliers (CMOs, CROs) that might receive an FDA inspection based on what you’ve contracted for (manufacturing, clinical, etc.)

Cover 3 topics

- 1. Logic behind FDA supplier inspections
- 2. Overall inspection process
- 3. How to prepare and respond (including coordination with you)



© 2017 Cerulean Associates LLC

www.CeruleanILC.com

19

Prepare a Supplier for FDA

“How to Prepare” points:

- responsibilities under the contract
- key documents they should have on hand
- best practices for inspectional logistics
- best practices for behavior you expect during the inspection (responding to questions, etc.)
- verify you will be involved in any formal response
- timelines for follow-ups with your organization (weekly or daily meetings and teleconferences, etc.)
- consider hiring an independent consultant as a mock auditor or trainer to show them what to expect



© 2017 Cerulean Associates LLC

www.CeruleanILC.com

20

FAQ: “Should we show our supplier audit reports to FDA investigators?”

Caution! You are **currently** ONLY required to give FDA supplier audit reports under six limited circumstances
see www.fda.gov/CECI/ComplianceManuals/CompliancePolicyGuidanceManual/ucm073841.htm

That said...

- You are required to turn over to EMA, Health Canada, TGA, MHRA, etc.
- It may be in your best interest – if you are going more virtual – to provide the supplier audit report
- **Be aware** that with the upcoming inspectional program and policy changes with NIPP and MDSAP, this self-imposed FDA policy limit may change

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

21



Upon notification
Tasks just prior to the investigator's arrival
And if you're surprised...

PRE-INSPECTION ACTIVITIES

© 2017 Cerulean Associates LLC www.CeruleanILC.com 22

Upon Notification


- Letter or phone call
 - international inspections **used to be** only by 4-6 week "heads-up"...
- Determine:
 - any leeway on start date
 - can you send anything ahead of time (Site Inspection Proof Binder)
- Verify:
 - type of inspection (routine/risk-based, for cause, PAI, etc.)
 - scope and primary focus (closeout previous inspection, clinical trial, specific product, recall closeout, etc.)
 - investigators who will attend (**google them!**)
 - anticipated length (days, weeks)

© 2017 Cerulean Associates LLC www.CeruleanILC.com 23

Upon Notification

Notify Senior Management and the Site Inspection Response Team (SIRT)

- consider inviting senior management to your *rapid review and prep session*
- depending on context, suggest notifying:
 - critical suppliers (CMOs, CROs, etc.)
 - other (subsidiary) sites
- give a draft site notification to be sent out to all site employees by the facility head (CEO, etc.)
 - scope of the inspection
 - dates of inspection
 - reminder of Site Inspection Response Team members (direct questions to)
 - reminder link to Regulatory Inspection Handling SOP
 - reminder link to corporate ethics policy



© 2017 Cerulean Associates LLC www.CeruleanILC.com 24

Upon Notification

- Conduct a rapid review and inspection prep session with the Inspection Response Team (and backups)
- expectations for how inspection will unfold
 - quickly refresh everyone about any previous inspection and results
 - schedule daily debriefing and review meetings
 - remind about rules surrounding special/restricted access areas (clean rooms, loud rooms, labs, etc.)
 - quick review of your Regulatory Inspection Handling SOP
 - quick review of your Site Inspection Proof Binder (update as necessary)
 - remind everyone of best practices for answering questions
 - clarify any current known open issues and status (e.g., recalls, etc.)
 - identify note-takers (make sure they also have a camera)

Helpful Checklist

In reference materials

- Divided into 2 sections:
- upon initial notification
 - prior to investigator arrival



And If You're Surprised....

- In "Bonus" section of reference materials
- 7-steps designed to carryout in less than 10 hours (although typically in less than 5-10 days if you're really thorough)



Interactive
Exercise



© 2017 Cerulean Associates LLC

www.CeruleanILlc.com

28

Greeting the investigators professionally
Turning the site tour to your advantage
Providing access
Responding to questions
Inspection observation-closure matrix
Some record do's and don'ts
Logging items requested v. provided

HANDLING ACTIVITIES




© 2017 Cerulean Associates LLC

www.CeruleanILlc.com

29

Inspection Flow



© 2017 Cerulean Associates LLC

www.CeruleanILlc.com

30

Checklist: Handling Inspection

In reference materials



© 2017 Cerulean Associates LLC www.Ceruleanllc.com 31

Greeting the FDA Investigators

- 1. If you have a logbook, make sure to have *each* investigator sign-in
- 2. If your site utilizes guest/visitor badges, provide to *each* investigator
- 3. Verify the investigator's credentials
 - do NOT try to photocopy his/her credentials (18 USC § 701)
- 4. Escort the investigators to a meeting room (or your prepared inspection/audit room)
 - offer/provide professional refreshments (non-alcoholic drinks)
- 5. Notify each member (or backup) of the Site Inspection Response Team
- 6. Obtain a copy of the Form FDA 482, Notice of Inspection (US only)
 - this should include investigator(s) name, purpose of inspection
 - verify the form has the right company name and address
- 7. Provide a copy of the Site Inspection Proof Binder
 - if current and you've not already provided

© 2017 Cerulean Associates LLC www.Ceruleanllc.com 32

Turning a Tour to Your Advantage

Reminder: this **NOT** a typical show-and-tell

Goal: Showcase physical controls

- locked and secured areas
- calibration labeling
- labeling of storage areas, cabinets, etc.
- cleanliness and orderliness ("everything in its place and a place for everything")
- controls over special areas (clean rooms, labs, etc.)
- workflow "gates"
- any alarmed doors, security video cameras, etc.



!CAUTION!
Any cameras used in production or CAPAs are open to inspection

© 2017 Cerulean Associates LLC www.Ceruleanllc.com 33

Providing Access

- Escort the investigators at all times
 - a known tactic is to try to “escape” the escort
 - make sure the investigators gown up, etc. for special controlled areas!
- Log records requested v. given
 - consider making duplicate copies of any copy provided
- Have a dedicated note-taker document
 - significant items
 - questions and answers
 - areas visited within site
 - photographs taken (consider taking your own)



Responding to Questions

- Be honest and cooperative
- HOWEVER...
 “If you don’t need to say, it’s best to stay silent”
- Preface answers with “To the best of my knowledge....”
- Refer to SOPs, policies or widely recognized industry standards (such as ISO, GAMP, ICH, IMDRF, etc.)
- Be careful referring to FDA guidance documents
- Whenever unsure – refer to the company expert or a member of the Site Inspection Response Team
- Avoid arguing with the investigators

Responding to Affidavits

- Do NOT sign
- Do NOT listen (yes, you can walk away)
- Do NOT handle, review, skim through, etc.
- Do NOT initial or correct any errors

Contact your legal counsel immediately

Tracking Progress

- With **Investigators** and **Site Inspection Response Team**
- daily debriefs or inspection summaries with FDA
 - use this time to ask questions/clarifications and show any fixes

- Follow with a private **Site Inspection Response Team** review
- share impressions
 - discuss potential corrective actions
 - quick fixes (and proof to provide the investigators)
 - longer term fixes (and proof to provide)
 - update senior management

Observation-Closure Matrix

- Keep simple to allow easy tracking and rapid review
- Use in debriefing meetings
- Use in closeout meeting
- Use to help formulate responses (and proof)
- Don't forget to open a nonconformance or CAPA

Inspectional Observation	Owner / Accountable	Status	Proof (documents)

Template: Observation-Closure

- In reference materials
- use during inspections
 - use during follow-up
 - use during internal quality audits



During a regulatory inspection, the investigator asks for a specific record. After 24 hours, you cannot find it. Which response is best?

- a) Give us another 24 hours to locate the record
- b) The record is at another site
- c) We noted a discrepancy and opened a CAPA

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

40

Reasonable Record Turn-Around

For records onsite: **less than 1 hour**

For records offsite: **4-24 hours**

For e-records on archived media: **4-18 hours**

For records at a supplier: **3-6 hours**

- Can your suppliers provide record review via webinar?

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

41

Some Record Do's and Don'ts

- Do **NOT** provide investigator with original documents to take with him/her
 - make sure to follow your SOP on making copies of controlled documents!
 - strongly consider stamping COPY on it and using different colored paper....
 - call District Office immediately if investigators insist on taking originals
- Do **NOT** provide any confidential/trade secret documents without clear demarcation on the documents
- Do **NOT** inhibit investigators from taking photographs
- Do **NOT** hide records from investigators (or redact items within a document)

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

42

Some Record Do's and Don'ts


- Do **NOT** create false records (including completing any blanks in already filed forms) to fill in gaps in record trail
- **DO** explain if you cannot find or produce a record (printer or copier is broken or jammed, the record is in transit to an outsourced provider, USB drives are locked, etc.)
- **DO** verify investigator's request in your lingo (does a request for a "quality manual" mean "all your SOPs and policies" or your Site Master File or ...?)

Logging Requests v. Provided

Item #	Item Requested	Description/Intent	Date Requested	Date Provided	Provided by

Interactive Exercise





Managing the closeout meeting
Immediately after the closeout

CLOSEOUT ACTIVITIES

© 2017 Cerulean Associates LLC www.Ceruleanllc.com 46

Managing the Closeout Meeting

- **Senior management must attend** (preferably in person)
- All primary members of the Site Inspections Response Team should also attend
- Treat the investigators like the professionals they are
- Listen for opportunities where you can go beyond the observation to demonstrate “good faith”
- Remember that the Center and ORA now make the final determination on deficiencies
- **Only pushback with supporting, objective evidence** like guidance documents, industry consensus standards, and company records

© 2017 Cerulean Associates LLC www.Ceruleanllc.com 47

Understanding Each Observation

- Discuss deviations and other observations – get clarity on expectations v. concerns
 - ask questions around obtaining clarity (avoid asking to release any non-conforming products, continue with unsafe trials, etc....)
- Understand the basis for each observation
 - what are the underlying facts supporting the observation
 - what records/samples/photos support the observation
 - what are your regulatory v. guidance obligations
- If you are confused by an observation, ask, ask, and ask again
 - avoid stating in any written response that the company is confused....
- Try to get investigator’s viewpoint and resolution suggestions/opinion (“if we did ... / Would that ...?”)
- Discuss and make sure you grasp the larger, systemic issues that these “snapshot in time” observations represent

© 2017 Cerulean Associates LLC www.Ceruleanllc.com 48

Closeout Meeting Do's

- **DO** remember that just because it's not on the Form FDA-483 doesn't mean it won't end up in a Warning Letter
- **DO** treat the inspection work products as professional products
- **DO** display a willingness to understand and make the expected corrections
- **DO** find opportunities where you can go beyond gap closure to demonstrate you "get it"
- **DO** pushback when you have clear supporting evidence such as guidance documents and specific company records as objective evidence

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

49

Closeout Meeting Do's

- **DO** write down any next steps/timeframes, investigator comments or suggestions, etc.
- **DO** only commit orally to those actions and resolutions you have control over (e.g., be careful about committing on behalf of suppliers)
- **DO** be conservative in any corrective action timeframes

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

50

Closeout Meeting Don'ts

- Do **NOT** pull out your iPhone/smartphone and start texting, or calling, or Face Timing....
- Do **NOT** make commitments without knowing resources/time required
- Do **NOT** tell the investigator you need a "stiff one" and ask if he/she will join you
- Do **NOT** beg for forgiveness, complain like it's a death sentence, etc.
- Do **NOT** pull out resume and ask if the FDA has any open positions

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

51

Closeout Meeting Don'ts

- Do **NOT** scoff or take a “yeah, right” attitude
- Do **NOT** take notes for calling the *Wall Street Journal* or *USA Today* to give them your side of the story
- Do **NOT** casually place on the table a draft press release, blog post or letter to your Congressman supporting FDA budget cuts
- Do **NOT** ask if you can delay your response while you go on vacation (especially to an upscale location)
- Do **NOT** threaten or otherwise try to intimidate the investigators

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

52

Closeout Meeting Don'ts

- Do **NOT** ask what might...you know... “influence your decision...?”
- Do **NOT** claim that inspection findings will “put us out of business”
- Do **NOT** complain that “no one else does this” (or vice versa)
- Do **NOT** point out that no one “actually died”
- Do **NOT** grumble that all this “paperwork won’t make our product better”
- Do **NOT** suggest that the investigator doesn’t understand your industry

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

53

Closeout Meeting Don'ts

- Do **NOT** blame all observations on poor training or “stupid employees”
- Do **NOT** remind the investigator that previous inspections didn’t write up a particular FDA-483 observation
- Do **NOT** intimate that the investigator is ignorant/naïve because “we hired ex-FDA guys and they didn’t find anything wrong”

© 2017 Cerulean Associates LLC

www.CeruleanILC.com

54

Immediately Afterward

- Hold a post-inspection Site Inspection Response Team meeting
 - treat as private daily debrief meeting
 - review Inspection Observation-Closure Matrix
 - what needs to be updated?
 - what did the investigators believe was effectively closed?
 - do you have the right people assigned to open items?
 - are the timeframes and resources required appropriate?
 - can you also “go above and beyond” during the corrections within those timeframe and resources?
 - identify next steps for drafting the response

© 2017 Cerulean Associates LLC

www.Ceruleanllc.com

55

Picture Credits

Photos, images and clip art that appear on these slides have been used to enhance this presentation and may NOT be used for commercial or promotional purposes without permission from copyright holders. Do not remove or copy from this presentation.

Contact:
Microsoft Corporation
iStockPhoto
FDAnews
Cerulean Associates LLC

© 2017 Cerulean Associates LLC

www.Ceruleanllc.com

56
